Thus, CaMKII presents as an appealing treatment target for diabetic cardiomyopathy, allowing the hypothetical clinician to treat many of the downstream effects of DM with one targeted therapy. This evidence concerns the gene CAMK2G and diabetic cardiomyopathy.